Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma

This study has been completed.

Sponsor:

Collaborator:

National Cancer Institute (NCI)

Information provided by (Responsible Party):

Sidney Kimmel Comprehensive Cancer Center

ClinicalTrials.gov Identifier:

NCT00112736

First received: June 2, 2005

Last updated: November 29, 2012

Last verified: November 2012

History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Estimated Study Completion Date:	No date given
Primary Completion Date:	April 2010 (Final data collection date for primary outcome measure)

Publications:

Chang SM, Kuhn J, Lamborn K: Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas (MG) (NABTC 04-02). [Abstract] J Clin Oncol 27 (Suppl 15): A-2004, 2009.

Robins HI, Wen PY, Chang SM, et al.: Phase I study of erlotinib and CCI-779 (temsirolimus) for patients with recurrent malignant gliomas (MG) (NABTC 04-02). [Abstract] J Clin Oncol 25 (Suppl 18): A-2057, 2007.

To Top